Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (27784)	2/3/1999 9:04:00 PM
From: Henry Niman	Respond to of 32384

bob, Today's Panretin approval is an excellent example of how LGND's technology works and how it brings products to market. Before Ligand was even formed, scientists in Ron Evans' lab were working on a new class of retinoic acid receptors, classified as RXRs because although they were closely related to retinoic acid receptors (RARs), they were not activated by retinoic acid. Panretin (9-cis retinoic acid), was discovered as an isomer that would not only activate the three RXRs, but also the three RARs, hence it was named PANretin. It was also determined that the drug was a natural hormone in the non-polypeptide category, the first to be discovered in 25 years. LGND then developed Panretin as their lead compound and they formed ALRT to help fund the clinical development. LGND's more advance technology targets intracellular receptors like RXRs and RARs and their other products in the clinic (SERMs) target another IR, the estrogen receptor. They also have advanced progestin and androgen receptor programs, and all target IRs, as does their TZD program which targets PPARs. Today's approval validates LGND's ability to not only discover these drugs of the future, but to also take them through to the marketplace.

To: bob zagorin who wrote (27784)	2/16/1999 12:06:00 AM
From: Henry Niman	Respond to of 32384

Interesting article in today's Annals of Internal Medicine. Elevated levels of estrogens and androgens correlate with increased risk for breast cancer. Could have implications for heard to head prevention trial between Tamoxifen and Evista and suggests that LGND's SERM's (PFE's Droloxifene and CP-366,156; and AHP's TSE424) and SARMs (Selective Androgen Receptor Modifiers) could have breast cancer prevention applications. Details linked to SERM page of New Therapeutics: biocognizance.com

To: bob zagorin who wrote (27784)	2/16/1999 8:12:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

BBC and LT are carrying stories this morning on ZEN's Tamoxifen and increased risk for Endometrial Cancer. ERT (like AHP's Premarin) has also been associated with increased risk for Endometrial Cancer. AHP has a SERM, TSE424, in early clinical trials for osteoporosis. PFE also has a couple of SERMs (Droloxifene and CP-366,156) in the clinic as does SBH (Idoxifene). LLY's Evista is in a head to head trials against Tamoxifen in breast cancer prevention trials. Details in SERM table in New Therapeutics section: biocognizance.com